Research paper
Drug Repurposing: A Systematic Approach to Evaluate Candidate Oral Neuroprotective Interventions for Secondary Progressive Multiple Sclerosis
Study answer
What this study found
The review identified ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and the polyunsaturated-fatty-acid class as lead oral candidates for further testing in secondary progressive MS. Fluoxetine had the clearest direct MS signal in the provided text: one mainly relapsing-remitting trial showed a significant reduction in relapse rate incidence and new inflammatory lesions, and another progressive-cohort trial showed favorable trends including reduced EDSS scores and improved 9 Hole Peg Test performance. The authors present this as an evidence-led repurposing pipeline…
- Study & population
- Systematic review and evidence-synthesis framework for progressive multiple sclerosis, especially secondary progressive MS.
- Intervention
- This systematic review did not test one supplement regimen; it evaluated licensed oral neuroprotective candidates for secondary progressive multiple sclerosis, including ibudilast, riluzole, amiloride, pirfenidone, fluoxetine, oxcarbazepine, and a polyunsaturated fatty-acid class (including linoleic acid, lipoic…
- Key limitation
- The evidence base was heterogeneous across diseases, populations, and mechanisms, so much of the support is indirect rather than SPMS-specific.
View source
Open PDFOriginal abstract
Objective To develop and implement an evidence based framework to select, from drugs already licenced, candidate oral neuroprotective drugs to be tested in secondary progressive multiple sclerosis. Design Systematic review of clinical studies of oral…